β-blockers have been widely utilized as a part of acute myocardial infarction (AMI) treatment for the past 40 years. Patients receiving β-adrenergic blockers for an extended period following myocardial infarction have a higher chance of surviving. Although many patients benefited from β-blockers, many do not, including those with myocardial infarction, left ventricle dysfunction, chronic pulmonary disease, and elderly people. In individuals with post-acute coronary syndrome and normal left ventricular ejection fraction (LVEF), the appropriate duration of beta-blocker therapy is still unknown. There is also no time limit for those without cardiac angina and who do not need β-blockers for dysrhythmia or hypertension. Interestingly, β-blockers have been prescribed for more than four decades. The novel mechanism of action on cellular compartments has been found continually, which opens a new way for their potential application in cardiac failure and other cardiac events like post-myocardial infarction. Here, in this review, we studied β-blocker usage in these circumstances and the current recommendations for β-blocker use from clinical practice guidelines.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of drugs that lower blood glucose levels while decreasing blood pressure, volume loss, and weight loss. SGLT2 inhibitors were studied to determine their effectiveness in treating cardiovascular disease and their side effects. Study outcomes related to cardiovascular and metabolic outcomes were examined in patients on SGLT2 inhibitors by searching PubMed, Embase, Cochrane, and SCOPUS. Articles related to clinical trials, reviews, and meta-analyses were considered. A review of SGLT2 inhibitors' mechanisms of action in preventing cardiovascular (CVS) disease progression was described. We then reviewed the possible effects of SGLT2 inhibitors on CVS dysfunction development, composition, and stability. In the following, we discussed the impact of SGLT2 inhibitors on CVD events, such as ischemic strokes and myocardial infarctions, and their role in treating congestive heart failure and cardiovascular mortality.

Background: Chronic liver disease (CLD) is a condition of liver damage that includes cirrhosis and fibrosis of liver. It is a progressive destruction of liver functions due to inflammation, exertion of bile and detoxification of harmful products of metabolism. Objective : To assess the prescribing pattern in chronic liver disease patients and to facilitate rational use of medication. Method : A uni-centric prospective (observational) study was conducted for a period of 6 months for analyzing the prescribing pattern used in treating Chronic Liver Disease (CLD) patients. All the patients (both male and female) diagnosed with CLD visited to gastroenterology department were included in the study. Patients with pregnancy, age below 18 year and above 80 year were not involved in the study. Result: It was observed that the number of males accounted for the 64% of the total patients and rest 36% were females. CLD affected the age group of 48 – 58 years and the common causes were hepatitis C virus (55.55%) and alcohol consumption (26.19%).